Last reviewed · How we verify

bupivacaine S75:R25 plus 8% glucose

Cristália Produtos Químicos Farmacêuticos Ltda. · Phase 3 active Small molecule

bupivacaine S75:R25 plus 8% glucose is a Local anesthetic Small molecule drug developed by Cristália Produtos Químicos Farmacêuticos Ltda.. It is currently in Phase 3 development for Local anesthesia for surgical procedures, Pain management for chronic conditions.

Bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses. Used for Local anesthesia for surgical procedures, Pain management for chronic conditions.

At a glance

Generic namebupivacaine S75:R25 plus 8% glucose
SponsorCristália Produtos Químicos Farmacêuticos Ltda.
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

This prevents the transmission of pain signals to the brain, resulting in a loss of sensation in the affected area. Bupivacaine is a long-acting local anesthetic, providing prolonged pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about bupivacaine S75:R25 plus 8% glucose

What is bupivacaine S75:R25 plus 8% glucose?

bupivacaine S75:R25 plus 8% glucose is a Local anesthetic drug developed by Cristália Produtos Químicos Farmacêuticos Ltda., indicated for Local anesthesia for surgical procedures, Pain management for chronic conditions.

How does bupivacaine S75:R25 plus 8% glucose work?

Bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulses.

What is bupivacaine S75:R25 plus 8% glucose used for?

bupivacaine S75:R25 plus 8% glucose is indicated for Local anesthesia for surgical procedures, Pain management for chronic conditions.

Who makes bupivacaine S75:R25 plus 8% glucose?

bupivacaine S75:R25 plus 8% glucose is developed by Cristália Produtos Químicos Farmacêuticos Ltda. (see full Cristália Produtos Químicos Farmacêuticos Ltda. pipeline at /company/crist-lia-produtos-qu-micos-farmac-uticos-ltda).

What drug class is bupivacaine S75:R25 plus 8% glucose in?

bupivacaine S75:R25 plus 8% glucose belongs to the Local anesthetic class. See all Local anesthetic drugs at /class/local-anesthetic.

What development phase is bupivacaine S75:R25 plus 8% glucose in?

bupivacaine S75:R25 plus 8% glucose is in Phase 3.

What are the side effects of bupivacaine S75:R25 plus 8% glucose?

Common side effects of bupivacaine S75:R25 plus 8% glucose include Numbness, Dizziness, Headache.

What does bupivacaine S75:R25 plus 8% glucose target?

bupivacaine S75:R25 plus 8% glucose targets Voltage-gated sodium channels and is a Local anesthetic.

Related